Ages =<  years of age with chronic lymphocytic leukemia (CLL)
T-cell large granular lymphocytic leukemia
Lymphoma fulfilling the following criteria: Chemotherapy-sensitive (at least stable disease lymphomas that have failed at least  prior regimen of multi-agent chemotherapy and are INELIGIBLE for an autologous transplant. Patients with chronic lymphocytic leukemia (CLL) are not eligible regardless of disease status.
Group B: CD+ B cell chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) undergoing allogeneic HSCT
Patient must have diagnosis of CLL that meets published  International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institutesponsored Working Group (NCI-WG) criteria
Diagnosis of chronic lymphocytic leukemia (CLL) meeting criteria established in the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)  criteria for the diagnosis and treatment of CLL
Ages =<  years with chronic lymphocytic leukemia (CLL)
No treatment indication according to IWCLL/NCI-WG (International Working Group in Chronic Lymphocytic Leukemia/National Cancer Institute-Working Group)  criteria.
Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute (NCI)-Working Group (WG) criteria, and relapsed after or refractory to at least  prior treatment
Chronic lymphocytic leukemia with high risk disease as defined by the European Society for Blood and Marrow Transplantation (EBMT) consensus criteria
Diagnosis of B-cell chronic lymphocytic leukemia (B-CLL), confirmed by flow cytometry and as per the criteria outlined by the IWCLL/Hallek December 
Histologically or cytologically confirmed Hodgkin and all NHL subtypes excluding Burkitt, chronic lymphocytic leukemia (CLL) and lymphoblastic lymphoma that is considered to have relapsed or to be refractory to primary chemotherapy
Clinically significant and ongoing immune suppression including, but not limited to, systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection, or solid organ transplantation
Must have a confirmed diagnosis of CLL defined by  International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
Indication for treatment as defined by the International Workshop in Chronic Lymphocytic Leukemia (IWCLL) Guidelines
Patients with active chronic lymphocytic leukemia (CLL) disease requiring urgent chemotherapy
Diagnosis of B-CLL, confirmed by flow cytometric analysis and as per the criteria outlined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/Hallek December 
Diagnosis of chronic lymphocytic leukemia with no history of previous treatments with monoclonal antibodies or chemotherapy.
Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia
Secondary immune thrombocytopenia from any cause including lymphoma, chronic lymphocytic leukemia, and drug-induced thrombocytopenia
Diagnosis of active CLL or SLL that meets at least  of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)  criteria for requiring treatment
Diagnosis of chronic lymphocytic leukemia (CLL) meeting criteria established in the World Health Organization (WHO) classification of hematologic disorders or International Workshop on Chronic Lymphocytic Leukemia (IWCLL)
Known immunosuppressive disease, for example HIV infection or history of bone marrow transplant or chronic lymphocytic leukemia (CLL).
FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL):
Histologically confirmed diagnosis of recurrent B-cell non-Hodgkin's lymphoma (any\n             histology by WHO criteria) or recurrent chronic lymphocytic leukemia (by NCI\n             criteria) (Reference Appendix C)
Pathologic diagnosis per local institutional review of Richter syndrome that transformed from chronic lymphocytic leukemia (CLL).
Diagnosis of Chronic Lymphocytic Leukemia (CLL) established according to International Workshop Chronic Lymphocytic Leukemia (IWCLL) criteria.
Known transformation of Chronic Lymphocytic Leukemia (CLL) to an aggressive B-cell malignancy at the time of screening
Cohort : Participants must have chronic lymphocytic leukemia.
Known immunosuppressive disease, for example HIV infection or history of bone marrow transplant or chronic lymphocytic leukemia (CLL)
Treatment nave or previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment
Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
Patients must have an indication for treatment by  International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria
Treatment-nave CLL patients must meet the following requirements (Phase II only):\r\n* Symptomatic disease as defined by International Workshop on Chronic Lymphocytic Leukemia (IWCLL)  criteria\r\n* Received no prior chemotherapy, immunotherapy, or targeted therapy for the treatment of CLL with the exceptions of palliative loco-regional radiotherapy and corticosteroids for symptom control
Clinically significant and ongoing immune suppression including, but not limited to, systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection, or solid organ transplantation
Chronic lymphocytic leukemia (CLL).
Previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment
CLL/SLL patients must have:\r\n* Indication for treatment according to the  International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria\r\n* Received at least one prior standard treatment regimen
Documented previously untreated CLL according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria
Subject must have a diagnosis of CLL that meets  Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) criteria
Diagnosis of CLL per diagnostic criteria for relapsed or refractory CLL per the international workshop on chronic lymphocytic leukemia (iwCLL) guidelines
Diagnosis of relapsing/refractory or previously untreated chronic lymphocytic leukemia
Active disease meeting at least  of the International Workshop on Chronic Lymphocytic Leukemia  criteria for requiring treatment
Prior treatment for chronic lymphocytic leukemia.
Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), previously untreated, Rai stage -ll
Ages =<  years of age with chronic lymphocytic leukemia (CLL)
Chronic lymphocytic leukemia that has failed induction therapy or Rai stages -
Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia [Hallek, ]).
Relapsed or refractory Chronic Lymphocytic Leukemia and require treatment in opinion of investigator
Diagnosis of B-cell CLL, established according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and having received at least  prior treatment regimens
Diagnosis of B-cell CLL, with diagnosis established according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL)
Diagnosis of Chronic lymphocytic leukemia or Small lymphocytic lymphoma that meets at least one of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)  criteria for treatment (Binet Stage ? B and/or Rai Stage ? I with symptoms)
History of chronic leukemias (eg, chronic lymphocytic leukemia).
Documented diagnosis of B-cell CLL, according to International Workshop on Chronic Lymphocytic Leukemia 
Clinically significant and ongoing immune suppression including, but not limited to, systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection, or solid organ transplantation
T cell large granular lymphocytic leukemia
Chronic lymphocytic leukemia (CLL)
At least two prior treatment regimens for chronic lymphocytic leukaemia.
Patients with chemo-sensitive chronic lymphocytic leukemia (CLL) with persistent or recurrent disease after fludarabine-based regimens, no evidence of \bulky\ disease (>  cm in diameter)
Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria
Prior exposure to ABT- or B-cell chronic lymphocytic leukemia (CLL)/lymphoma  (BCL) inhibitors
Chronic lymphocytic leukemia (CLL) patients with IgG less than  mg/dl with/without symptoms who are either untreated or previously treated, regardless of response, at least  months from prior therapy (including monoclonal antibody [mAb])
Chronic lymphocytic leukemia (CLL).
Active cancer or metastatic disease, except in the case of stage  chronic lymphocytic leukemia or nonmelanoma skin cancer
Active cancer diagnosis or metastatic disease, except in the case of stage  chronic lymphocytic leukemia or nonmelanoma skin cancer
Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per International Workshop on Chronic Lymphocytic Leukemia (IW-CLL)  criteria with biopsy proven transformation to diffuse large B cell lymphoma (DLBCL), consistent with Richters Syndrome
Food and Drug Administration (FDA)-approved indications for idelalisib of relapsed, histologically confirmed B-cell indolent non-Hodgkin lymphoma (iNHL) or chronic lymphocytic leukemia (CLL)
Patient has a diagnosis of chronic lymphocytic leukemia
Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
